Skip to content

Diego A Pizzagalli

Harvard Medical School, McLean Hospital, Belmont, Massachusetts.

3 papers in the library · 9 citations · publishing 2025-2026

Papers

Environmental determinants of ketamine's prohedonic and antianhedonic efficacy: Persistence of enhanced reward responsiveness is modulated by chronic stress.

The Journal of pharmacology and experimental therapeutics May 1, 2025 Amaya R Jenkins, Daniela B Radl, Thomas J Kornecook et al. 8 citations

Ketamine produces short-lived increases in reward responsiveness in rats under nonstressful conditions, but under ongoing chronic stress it rescues blunted reward responsiveness for nearly one week. These findings highlight the role of environmental context in ketamine's effects on reward processing and suggest its antianhedonic action may contribute to its antidepressant efficacy.

Ketamine Improves Anhedonic Phenotypes Across Species: Translational Evidence From the Probabilistic Reward Task.

Biological psychiatry global open science May 1, 2026 Mario Bogdanov, Jason N Scott, Shiba M Esfand et al. 1 citation

A single low dose of ketamine improves the ability to learn from rewards in both people with treatment-resistant depression and stressed rats, using nearly identical tasks. Twenty-four hours after receiving ketamine, individuals with treatment-resistant depression and chronically stressed rats showed a stronger tendency to choose the more frequently rewarded option, matching the performance of healthy controls. This effect was most pronounced in people with more severe anhedonia at the start. Ketamine did not affect general task accuracy, indicating it selectively boosts reward learning rather than overall performance. These findings point to a shared behavioral mechanism by which ketamine alleviates anhedonia, with potential implications for treating anhedonia in depression and related conditions.

Modulatory effects of ketamine on EEG source-based resting state connectivity in treatment resistant depression.

Translational psychiatry March 6, 2026 Ty Lees, Jason N Scott, Brian W Boyle et al.

A single low dose of ketamine (0.5 mg/kg) reduced depressive, anhedonic, and ruminative symptoms 24 hours later in 24 people with treatment-resistant depression. The symptom improvement was not linked to changes in brain connectivity but was associated with connectivity patterns present before the infusion. After ketamine, participants showed broad increases in resting-state functional connectivity within and between the default mode and frontoparietal networks, as measured by EEG. The authors suggest these connectivity increases may reflect ketamine's synaptogenic effects, which can be short-lived. The study included 34 healthy controls who did not receive ketamine.